Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bruchas MR, Chavkin C (2010). Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl) 210: 137–147.
Bruchas MR, Yang T, Schreiber S, Defino M, Kwan SC, Li S et al (2007). Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J Biol Chem 282: 29803–29811.
Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C (2008). The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci 28: 407–414.
Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens Jr WC et al (2003). Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305: 323–330.
McLaughlin JP, Marton-Popovici M, Chavkin C (2003). Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23: 5674–5683.
Melief EJ, Miyatake M, Bruchas MR, Chavkin C (2010). Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci USA 107: 11608–11613.
Millan MJ (1990). Kappa-opioid receptors and analgesia. Trends Pharmacol Sci 11: 70–76.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
C Chavkin has no conflicts of interest or consulting relationships to disclose, but has received outside compensation for seminars on his NIH-funded research during the past 3 years at: AstraZeneca, NIDA, UC Irvine, Uniformed Services University, University of Minnesota, Sepracor, Eli Lilly, Adolor, and Vanderbilt. In addition, he has received outside compensation for reviewing grants for CSR-NIH and NIDA.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Chavkin, C. The Therapeutic Potential of κ-Opioids for Treatment of Pain and Addiction. Neuropsychopharmacol 36, 369–370 (2011). https://doi.org/10.1038/npp.2010.137
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2010.137
This article is cited by
-
Effects of the novel selective κ-opioid receptor agonist NP-5497-KA on morphine-induced reward-related behaviors
Scientific Reports (2023)
-
Social approach and social vigilance are differentially regulated by oxytocin receptors in the nucleus accumbens
Neuropsychopharmacology (2020)
-
Agonist-induced phosphorylation bar code and differential post-activation signaling of the delta opioid receptor revealed by phosphosite-specific antibodies
Scientific Reports (2020)
-
Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys
Psychopharmacology (2020)
-
Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development
European Journal of Nuclear Medicine and Molecular Imaging (2020)